ESMO 2021 | Precision medicine in urothelial carcinoma

Enrique Grande, MD, PhD, MD Anderson Cancer Center Madrid, Madrid, Spain, discusses advances in precision medicine in the field of urothelial carcinoma (UC). In 2019, the FDA approved erdafitinib, a FGFR inhibitor, for the treatment of relapsed patients with locally advanced or metastatic UC with specific FGFR mutations. To implement biomarkers in clinical practice, it is important to conduct randomized biomarker-driven clinical trials. Recently, a phase II study suggested the use of EphrinB2 as a biomarker identifying patients that could benefit from combination therapy with sEphB4-HSA and pembrolizumab (NCT02717156). Further research needs to be conducted to investigate when targeted treatments should be used during the disease course, as well as which combinations work best. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.